Pharsight

Drugs that contain Afatinib Dimaleate

1. Gilotrif patents expiration

GILOTRIF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(1 year, 10 months from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jul, 2026

(2 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(2 years from now)

US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
May, 2027

(3 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Dec, 2029

(5 years from now)

US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(6 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(6 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(6 years from now)

US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M (M) Apr 7, 2025
Pediatric Exclusivity (PED) Oct 7, 2025

Market Authorisation Date: 12 July, 2013

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents